Investigating how Epstein-Barr Virus contributes to certain cancers
Official title: Targeting the Epigenetic and Metabolic Control of EBV-Epithelial Cancers
Funded at Wistar Institute · NIH-11085157 · Data updated 2026-11-12
This study is looking into how the Epstein-Barr Virus might contribute to certain types of cancers, like stomach and throat cancer, to find new ways to treat these diseases and help those affected.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | May 11, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $2,420,381 |
| NIH project number | 5P01CA269043-03 |
| Project ID | NIH-11085157 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with EBV-associated epithelial cancers, such as gastric carcinoma or nasopharyngeal carcinoma.
✕Less likely to help
Patients with cancers not associated with Epstein-Barr Virus or those without epithelial cancer types may not benefit from this research.
What this research studies
This research focuses on understanding the role of Epstein-Barr Virus (EBV) in causing epithelial cancers, which are linked to over 200,000 new cancer cases annually. The project aims to explore the mechanisms through which EBV influences cancer development, particularly in gastric and nasopharyngeal carcinomas. By examining the interplay between viral infection, genetic mutations, and metabolic changes, the research team seeks to identify potential therapeutic targets. The collaborative effort involves experts in virology, cancer biology, and drug discovery to develop new treatment strategies for these challenging cancers.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies for EBV-associated epithelial cancers, improving patient outcomes.
How similar studies have gone: While the specific approach of targeting EBV-related cancers is innovative, there have been successful studies exploring viral contributions to cancer, indicating potential for this research.
Where this research is happening
-
Wistar Institute
Philadelphia, United States Active
Researchers
- Principal investigator: Lieberman, Paul M. — Wistar Institute
- Study coordinator: Lieberman, Paul M.
Related research
Other NIH-funded projects on the same topics.
-
Immunomodulation to Fight Cancer Spread
A cancer-focused training opportunity to learn how tumors and the immune system interact during cancer spread and use that knowledge to develop new immunotherapies.
-
Broadly neutralizing nanobodies to improve HIV therapy
Researchers are developing tiny antibodies called nanobodies to target HIV in new ways that could make treatments easier and more effective for people living with HIV.
-
BEAT-HIV: a collaborative effort to cure HIV with immunotherapy
A multi-institution study is testing a combination immunotherapy approach to achieve long-term HIV remission or cure for people on ART.
-
Epitope-engineered stem cells to enable HIV cure with targeted CAR-T therapy
A patient-focused plan to use a person’s own stem cells, edited to resist HIV and paired with specialized CAR-T cells, to clear HIV reservoirs.
-
Comprehensive bioinformatics support for cancer research at a leading cancer center
A cancer center-wide bioinformatics program helps researchers analyze data, build reusable data resources, and apply computational methods to cancer studies.
-
Refocusing HIV antibodies to target parts that block many strains
This project tries a new vaccine approach to steer the immune system to make antibodies that can block many types of HIV for people at risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.